| Catalog# |
C022 |
| Source |
E.coli |
| Description |
Recombinant Human Tumor Necrosis Factor Ligand Superfamily Member 10/TNFSF10 produced by our E. coli expression system is composed with the C- terminal extracellular domain including THD. The target protein is expressed with sequence (R115-G281) of Human TNFSF10. |
| Names |
Tumor Necrosis Factor Ligand Superfamily Member 10, Apo-2 Ligand, Apo-2L, TNF-Related Apoptosis-Inducing Ligand, Protein TRAIL, CD253, TNFSF10, APO2L, TRAIL |
| Accession # |
P50591 |
| Formulation |
Lyophilized from a 0.2 μm filtered solution of 150mM NaCl |
| Shipping |
The product is shipped at ambient temperature. |
| Reconstitution |
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in 1X PBS.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
| Storage |
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| Biological Activity |
ED50 is less than 2 ng/ml as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D.
Specific Activity of 5.0 x 106 IU/mg. |
| Purity |
Greater than 95% as determined by RP-HPLC and reducing SDS-PAGE. |
| Endotoxin |
Less than 0.1 ng/μg (1 IEU/μg). |
| Amino Acid Sequence |
MRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHE KGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIY QGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG
|
| Background |
Human TNFSF10 is a type II transmembrane protein with an intracellular N-terminus and a ‘TNF homology domain’ (THD) at the extracellular C terminus. TNFSF10 can interact with several distinct receptors. Two of these receptors that belongs to TNFR superfamily, DR4 (TRAIL-R1) and DR5 (TRAIL-R2/TRICK2), are plasma membrane proteins containing intracellular death domains essential for activating apoptosis. TNFSF10 is promising for cancer therapy because it is cytotoxic and activates apoptosis in the majority of malignant cells, but not in normal cells. |
